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The authors sought to examine the relation between serum or dietary magnesium and the incidence of ischemic
stroke among blacks and whites. Between 1987 and 1989, 14,221 men and women aged 45–64 years took part in
the first examination of the Atherosclerosis Risk in Communities Study cohort. The incidence of stroke was ascer-
tained from hospital records. Higher serum magnesium levels were associated with lower prevalence of hyperten-
sion and diabetes mellitus at baseline. During the 15-year follow-up, 577 ischemic strokes occurred. Serum
magnesium was inversely associated with ischemic stroke incidence. The age-, sex-, and race-adjusted rate ratios
of ischemic stroke for those with serum magnesium levels of 1.5, 1.6, 1.7, and 1.8 mEq/L were 1.0, 0.78 (95%
confidence interval (CI): 0.62, 0.96), 0.70 (95%CI: 0.56, 0.88), and 0.75 (95%CI: 0.59, 0.95) (Ptrend ¼ 0.005). After
adjustment for hypertension and diabetes, the rate ratios were attenuated to nonsignificant levels. Dietary magne-
sium intake was marginally inversely associated with the incidence of ischemic stroke (Ptrend ¼ 0.09). Low serum
magnesium levels could be associated with increased risk of ischemic stroke, in part, via effects on hypertension
and diabetes.
brain infarction; diet; magnesium; risk factors
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CI, confidence interval; CT, computerized tomography; HDL, high
density lipoprotein; LDL, low density lipoprotein; MRI, magnetic resonance imaging; RR, rate ratio.
Magnesium is a natural calcium antagonist and modulates
vasomotor tone, blood pressure, and peripheral blood flow.
Previous epidemiologic studies have reported that magne-
sium intake or serum magnesium levels are inversely asso-
ciated with cardiovascular risk factors such as hypertension
(1, 2), type 2 diabetes mellitus (1, 3), and the metabolic
syndrome (4). Therefore, low magnesium intake could in-
crease the risk of stroke, especially ischemic stroke, but few
prospective studies have reported the association of magne-
sium intake with the incidence of ischemic stroke (5, 6). The
Nurses’ Health Study reported that women in the highest
quintile of dietary magnesium intake had a 21% lower risk
of incidence of ischemic stroke compared with those in the
lowest quintile (6), but the association was not statistically
significant. The association of dietary magnesium intake
with the incidence of ischemic stroke could be modified
by other dietary minerals, such as calcium and potassium
(6). Further, the association between dietary and serum
magnesium is weak (1). Therefore, the mechanisms by
which low levels of magnesium lead to risk of ischemic
stroke may differ between dietary and serum magnesium,
and examining both dietary and serum magnesium could
provide further evidence on the association of magnesium
with the incidence of ischemic stroke. For instance, the joint
impact of high dietary magnesium intake and high serum
magnesium levels on the incidence of ischemic stroke could
be synergistic. No study, however, has reported such an
association.
In the Atherosclerosis Risk in Communities (ARIC)
Study, serum magnesium levels were inversely associated
Correspondence to Dr. Aaron R. Folsom, Division of Epidemiology and Community Health, School of Public Health, University of Minnesota,
1300 South 2nd Street, Suite 300, Minneapolis, MN 55454-1015 (e-mail: folso001@umn.edu).
1437 Am J Epidemiol 2009;169:1437–1444
with the incidence of hypertension and diabetes mellitus, but
dietary magnesium levels were not (3, 7). Further, another
ARIC Study demonstrated that serum magnesium levels
were inversely associated with the incidence of coronary
heart disease, but dietary magnesium levels were not (8).
Therefore, the associations between serum magnesium and
the incidence of ischemic stroke could be hypothesized to be
stronger than those between dietary magnesium and ische-
mic stroke. We further hypothesize that hypertension and
diabetes mellitus are important factors mediating the associ-
ation of serum magnesium with the incidence of ischemic
stroke.
To examine the relation of serum and dietary magnesium
with the incidence of ischemic stroke, we used data from
follow-up of men and women in the ARIC Study.
MATERIALS AND METHODS
Study population
The ARIC Study cohort comprised 15,792 men and
women aged 45–64 years between 1987 and 1989 in 4 US
communities: Forsyth County, North Carolina; Jackson,
Mississippi; 8 northwestern suburbs of Minneapolis, Min-
nesota; and Washington County, Maryland (9).
We excluded participants in Forsyth County who were not
white or black (n ¼ 21) and participants in Minneapolis and
Washington County who were not white (n ¼ 82). We then
excluded participants with a history of stroke or transient
ischemic attack at baseline (n ¼ 282) and participants with
missing data for serum or dietary magnesium (n ¼ 1,847) at
baseline. The remaining 13,560 participants (2,027 black
women, 1,266 black men, 5,481 white women, and 4,786
white men) were followed to determine the incidence of
stroke through 2004. The study protocol was approved by
the institutional review boards of the collaborating institu-
tions, and informed, written consent was obtained from each
participant.
Baseline measurements
Methods for blood processing in the ARIC Study have
been described (10). Participants were asked to fast for 12
hours before their morning clinic appointments. The mea-
surement of serum magnesium was based on the procedure
of Gindler and Heth and used the metallochromic dye,
calmagite (1-(1-hydroxy-4-methyl-2-phenylazo)-2-napthol-
4-sulfonic acid). The laboratory coefficient of variation, based
on blinded split samples sent 1 week apart to the laboratory,
was 3% (1), and repeated testing of 40 individuals over
several weeks yielded a reliability coefficient of 0.69 (11).
Plasma fibrinogen and the von Willebrand factor antigen
were measured by the thrombin time titration method and
enzyme-linked immunosorbent assay, respectively. Serum
glucose was measured by a hexokinase/glucose-6-phosphate
dehydrogenase method. Body mass index was calculated as
weight (kg)/height (m)2. We defined prevalent coronary
heart disease and stroke at baseline, for exclusion, as
a self-reported history of a physician-diagnosed heart attack,
prior myocardial infarction by electrocardiogram, prior car-
diovascular surgery, prior coronary angioplasty, or prior
stroke or transient ischemic attack identified by a standard-
ized interview (12).
Dietary information over the last year was collected by
using Willett’s 61-item food frequency questionnaire, adap-
ted for interviewer administration and otherwise modified
only slightly (13). Dietary magnesium intake was computed
by multiplying the magnesium content of each food item by
the frequency of its daily consumption and summing over all
items. In theARIC Study, serummagnesiumwas remeasured
for 91% of the participants in 1990–1992, and dietary
magnesium was remeasured for 82% in 1993–1995. The
Spearman correlation coefficients between 2 visits were
0.45 for serum magnesium and 0.54 for dietary magnesium.
The Spearman correlation coefficient between serum and
dietary magnesium at baseline was 0.04.
Endpoint determination
For the present study, we included stroke events (9) occur-
ring betweenARIC Study visit 1 (1987–1989) andDecember
31, 2004. Transient ischemic attacks were not ascertained.
All participants were contacted annually by phone, and all
hospitalizations and deaths in the previous year were identi-
fied.We also surveyed lists of discharges from local hospitals
and death certificates from state vital statistics offices for
potential cerebrovascular events. Abstractors recorded signs
and symptoms and photocopied neuroimaging (computer-
ized tomography (CT) or magnetic resonance imaging
(MRI)) and other diagnostic reports if the list of discharge
diagnoses included a cerebrovascular disease code (Interna-
tional Classification of Diseases, Ninth Revision, codes
430–438), if a cerebrovascular condition or procedure was
mentioned in the discharge summary, or if a cerebrovascular
finding was noted on a CT or MRI report. Of the stroke-
eligible hospitalizations through 1997, 84% had at least 1
CT scan, 27% had an MRI of the head, 15% had a cerebral
angiography, and 6% had a lumbar puncture (14). Each
eligible case was classified by computer algorithm and by
expert reviewer, according to criteria adapted from the
National Survey of Stroke (15). Details on quality assurance
for ascertainment and classification of stroke are described
elsewhere (14). Qualifying strokes were further classified
into definite or probable hospitalized ischemic (cardioem-
bolic or thrombotic) or hemorrhagic stroke on the basis of
neuroimaging studies and autopsy, when available.
Statistical analysis
Differences among the quartiles of serum or dietary mag-
nesium in age-, sex-, and race-adjusted mean values or prev-
alences of potential confounding factors at baseline were
calculated by using analysis of variance or logistic regres-
sion models, and their trends were tested by using linear
regression for continuous variables and logistic regression
for dichotomous variables. Median values of the serum or
dietary magnesium categories were used in these analyses.
The time at risk (time to event or time to censoring) was
calculated from the date of the baseline examination to the
earliest of the following: date of hospital admission for
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incident stroke, date of death, date of last follow-up contact,
or December 31, 2004. Because the number of hemorrhagic
stroke cases was small (n ¼ 87), we analyzed the associa-
tions of dietary or serum magnesium with the incidence of
ischemic stroke only.
The rate ratios of ischemic stroke incidence and 95% con-
fidence intervals relative to the lowest quartile of serum and
dietary magnesium were calculated, with adjustment for age
and other potential confounding factors, by using the Cox
proportional hazards model. We selected covariates on the
basis of previous prospective findings for ischemic stroke in
the ARIC Study (16, 17). Covariates included age (years),
sex, race-field center, smoking status (never, former, and
current smokers), body mass index (kg/m2), low density li-
poprotein (LDL) cholesterol (mg/dL), high density lipopro-
tein (HDL) cholesterol (mg/dL), fibrinogen (mg/dL), von
Willebrand factor (%), educational level (post-high school,
high school or less), and total energy intake (kcal/day). Un-
fortunately, the ARIC Study did not have information on
supplemental magnesium intake. Because we hypothesized
that hypertension and diabetes could mediate the association
between magnesium and ischemic stroke incidence, we in-
cluded systolic blood pressure (mm Hg), antihypertensive
medication use (yes, no), and diabetes status (yes, no) at
baseline in a final model. We tested interactions between
serum or dietary magnesium and sex, race, diuretic use, or
diabetes status for ischemic stroke based on comparison of
linear trends. Further, to quantify the relative contribution of
hypertension and diabetes status to the observed association
of magnesium with the incidence of ischemic stroke, we used
the following formula: (rate ratio (RR)basic model  RRadjusted
model)/(RRbasic model  1) 3 100% (18, 19). RRbasic model
represents the rate ratio for incidence of ischemic stroke ad-
justed for age, sex, and race, and RRadjusted model reflects the
rate ratio for incidence of ischemic stroke with additional
adjustment for systolic blood pressure, antihypertensive med-
ication use, and diabetes status.
RESULTS
Table 1 shows age-, sex-, and race-adjusted mean values
or prevalences of risk characteristics at baseline according
to quartiles of serum magnesium. Systolic blood pressure,
body mass index, and von Willebrand factor levels were
inversely associated with serum magnesium levels, and
LDL cholesterol and HDL cholesterol levels and dietary
magnesium intake were greater with increasing serum
Table 1. Age-, Sex-, and Race-adjusted Baseline Characteristics According to Serum Magnesium Levels,
Atherosclerosis Risk in Communities Study, 1987–1989
Quartiles of Serum Magnesium
Ptrend
1 (Low) 2 3 4 (High)
No. 3,619 3,529 3,431 2,947
Median, mEq/L 1.44 1.60 1.70 1.84
Range, mEq/L 1.50 1.51–1.60 1.61–1.79 1.80
Age, yearsa 54.2 54.0 54.2 54.3 0.40
Male, %b 41.5 45.6 45.5 46.3 <0.001
African Americans, %c 37.2 23.9 18.2 16.0 <0.001
Educational level (post-high school), % 39.8 44.8 44.9 47.6 <0.001
Body mass index, kg/m2 28.1 27.3 27.2 26.9 <0.001
Systolic blood pressure, mm Hg 123 120 120 119 <0.001
Use of antihypertensive medication, % 36.6 27.7 25.4 24.0 <0.001
Current smoking, % 26.3 25.8 26.5 24.8 0.26
Diabetes mellitus, % 17.9 9.7 7.1 5.6 <0.001
Low density lipoprotein cholesterol, mg/mL 134 137 139 141 <0.001
High density lipoprotein cholesterol, mg/mL 51.0 52.2 52.8 52.8 <0.001
Fibrinogen, mg/dL 304 301 300 302 0.11
von Willebrand factor, % 123 117 115 113 <0.001
Alcohol intake, g/week of ethanol 44.3 39.2 44.0 43.8 0.92
Total energy intake, kcal/day 1,623 1,631 1,630 1,627 0.67
Dietary calcium intake, mg/day 655 658 662 655 0.80
Dietary potassium intake, mg/day 2,629 2,630 2,641 2,655 0.23
Dietary sodium intake, mg/day 1,478 1,483 1,483 1,476 0.96
Dietary magnesium intake, mg/day 251 253 255 258 0.004
a Adjusted for sex and race.
b Adjusted for age and race.
c Adjusted for age and sex.
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magnesium levels. Higher serum magnesium levels were also
associated with a lower prevalence of antihypertensive medi-
cation use, diuretic use, and diabetes mellitus. Alcohol intake,
total energy intake, and dietary intake of calcium, potassium,
and sodiumwere not associatedwith serummagnesium levels.
As shown in Table 2, systolic blood pressure and LDL choles-
terol levels were inversely associated with dietary magnesium
intake, and HDL cholesterol levels, serum magnesium level,
alcohol intake, total energy intake, and dietary calcium, potas-
sium, and sodium intakes were positively associated with di-
etary magnesium intake.
Among the 13,560 men and women followed for an av-
erage of 15.0 years, 577 ischemic stroke cases occurred.
Participants with serum magnesium levels of 1.7 mEq/L
and 1.8 mEq/L had 30% and 25% lower age-, sex-, and
race-adjusted rate ratios of ischemic stroke than did those
with serum magnesium levels of 1.5 mEq/L, the rate ratio
being 0.70 (95% confidence interval (CI): 0.56, 0.88) and
0.75 (95% CI: 0.59, 0.95) (Table 3) (Ptrend ¼ 0.005). The
rate ratios were slightly attenuated by additional adjustment
for body mass index, smoking status, LDL cholesterol, HDL
cholesterol, fibrinogen, von Willebrand factor, and educa-
tional level, but they remained borderline significant (Ptrend ¼
0.05). However, further adjustment for other risk factors
that could be mediators between magnesium and ischemic
stroke—systolic blood pressure, use of antihypertensive
medication, and diabetes mellitus—attenuated the rate ra-
tios to nonsignificant levels. A large proportion (96%) of the
inverse association of serum magnesium with ischemic
stroke incidence was explained by hypertension (systolic
blood pressure and antihypertensive medication use) and di-
abetes status, when they were added to the regression model;
hypertension and diabetes contributed almost equally to the
attenuation of the magnesium association.
As shown in Table 4, there was a weak inverse association
between dietary magnesium intake and ischemic stroke
(Ptrend ¼ 0.09), and the association was essentially un-
changed after adjustment for systolic blood pressure, use
of antihypertensive medication, and diabetes mellitus. We
further divided the lowest quartiles into 2 groups using the
median value (quartile 1A, <12.5th percentile; quartile 1B,
12.5th–25th percentile). For serum magnesium, compared
with participants in quartile 1A, age-, sex-, and race-
adjusted rate ratios for those in the other groups were 0.63
(95% CI: 0.48, 0.84) for quartile 1B, 0.61 (95% CI: 0.47,
0.78) for quartile 2, 0.55 (95% CI: 0.42, 0.71) for quartile 3,
Table 2. Age-, Sex-, and Race-adjusted Baseline Characteristics According to Dietary Magnesium Levels,
Atherosclerosis Risk in Communities Study, 1987–1989
Quartiles of Magnesium Intake
Ptrend
1 (Low) 2 3 4 (High)
No. 3,306 3,315 3,321 3,335
Median, mg/day 152 213 271 362
Range, mg/day <186 186–241 242–307 >307
Age, yearsa 53.9 54.4 54.1 54.2 0.20
Male, %b 37.4 41.7 45.0 54.3 <0.001
African Americans, %c 32.4 24.5 20.9 18.5 <0.001
Educational level (post-high school), % 38.0 43.8 46.5 48.8 <0.001
Body mass index, kg/m2 27.3 27.3 27.4 27.5 0.25
Systolic blood pressure, mm Hg 121 121 121 120 0.02
Use of antihypertensive medication, % 29.7 29.5 28.4 27.4 0.02
Current smoking, % 26.1 25.0 24.7 27.2 0.23
Diabetes mellitus, % 10.1 10.3 9.6 11.0 0.22
Low density lipoprotein cholesterol, mg/mL 139 137 137 137 0.01
High density lipoprotein cholesterol, mg/mL 51.5 52.2 52.1 52.8 0.001
Fibrinogen, mg/dL 302 302 300 304 0.18
von Willebrand factor, % 118 118 115 117 0.55
Alcohol intake, g/week of ethanol 31.1 37.1 43.0 59.9 <0.001
Total energy intake, kcal/day 1,110 1,425 1,720 2,250 <0.001
Dietary calcium intake, mg/day 372 538 700 1,017 <0.001
Dietary potassium intake, mg/day 1,603 2,275 2,833 3,830 <0.001
Dietary sodium intake, mg/day 975 1,287 1,569 2,085 <0.001
Serum magnesium, mEq/L 1.63 1.63 1.64 1.64 0.02
a Adjusted for sex and race.
b Adjusted for age and race.
c Adjusted for age and sex.
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and 0.58 (95% CI: 0.44, 0.77) for quartile 4 (Ptrend¼ 0.002).
For dietary magnesium, compared with participants in quar-
tile 1A, age-, sex-, race-, and energy intake-adjusted rate
ratios for those in the other groups were 1.12 (95% CI:
0.80, 1.57) for quartile 1B, 1.10 (95% CI: 0.81, 1.48) for
quartile 2, 0.93 (95% CI: 0.66, 1.29) for quartile 3, and 0.83
(95% CI: 0.56, 1.24) for quartile 4 (Ptrend ¼ 0.12).
Furthermore, we analyzed the associations of serum and
dietary magnesium with the incidence of ischemic stroke
stratified by sex, race, antihypertensive medication use, di-
uretic use, hypertensive status, and diabetes status. There
were no interactions between serum or dietary magnesium
and sex, race, diuretic use, or diabetes status (Pinteraction >
0.10) for ischemic stroke, whereas the inverse association of
serum and dietary magnesium with the risk of ischemic
stroke tended to be stronger in whites than blacks. For serum
magnesium, compared with the lowest quartile, the age- and
sex-adjusted rate ratios of ischemic stroke for the highest
quartile were 0.70 (95% CI: 0.52, 0.95; Ptrend ¼ 0.01) for
whites and 0.83 (95% CI: 0.56, 1.23; Ptrend ¼ 0.13) for
blacks, and for dietary magnesium, the age-, sex-, and en-
ergy intake-adjusted rate ratios were 0.69 (95% CI: 0.45,
1.07; Ptrend ¼ 0.02) for whites and 1.01 (95% CI: 0.59, 1.73;
Ptrend ¼ 0.98) for blacks.
Table 5 shows age-, sex-, race-, and energy intake-adjusted
rate ratios of ischemic stroke according to combinations of
Table 3. Rate Ratios and 95% Confidence Intervals of Ischemic Stroke According to Serum Magnesium Levels, Atherosclerosis Risk in
Communities Study, 1987–2004
Quartiles of Serum Magnesium
Ptrend
1 (Low) 2 3 4 (High)
No. at risk 3,619 3,529 3,431 2,974
Median, mEq/L 1.44 1.60 1.70 1.84
Ischemic stroke
Person-years of follow-up 52,647 53,151 52,409 45,637
No. of cases 199 142 123 112
Incidence rate/1,000 person-years 3.8 2.7 2.3 2.5
Rate ratios (95% confidence interval)
Age, sex, and race adjusted Referent 0.78 (0.62, 0.96) 0.70 (0.56, 0.88) 0.75 (0.59, 0.95) 0.005
Multivariate adjusteda 0.81 (0.65, 1.01) 0.75 (0.60, 0.95) 0.83 (0.65, 1.05) 0.05
Multivariate adjustedb 0.94 (0.75, 1.17) 0.90 (0.71, 1.13) 1.04 (0.82, 1.32) 0.99
a Adjusted for age, sex, race-field center, smoking status, body mass index, low density lipoprotein cholesterol, high density lipoprotein
cholesterol, fibrinogen, von Willebrand factor, and educational level.
b Further adjusted for systolic blood pressure, use of antihypertensive medication, and diabetes mellitus.
Table 4. Rate Ratios and 95% Confidence Intervals of Ischemic Stroke According to Dietary Magnesium Levels, Atherosclerosis Risk in
Communities Study, 1987–2004
Quartiles of Magnesium Intake
Ptrend
1 (Low) 2 3 4 (High)
No. at risk 3,306 3,315 3,321 3,335
Median, mg/day 152 213 271 362
Ischemic stroke
Person-years of follow-up 49,752 49,636 50,475 50,019
No. of cases 140 154 134 131
Incidence rate/1,000 person-years 2.8 3.1 2.7 2.6
Rate ratios (95% confidence interval)
Age, sex, race, and energy
intake adjusted
Referent 1.03 (0.81, 1.31) 0.87 (0.66, 1.14) 0.78 (0.55, 1.09) 0.09
Multivariate adjusteda 1.09 (0.85, 1.38) 0.97 (0.74, 1.27) 0.89 (0.63, 1.25) 0.38
Multivariate adjustedb 1.08 (0.85, 1.37) 0.96 (0.73, 1.25) 0.80 (0.75, 1.13) 0.14
a Adjusted for age, sex, race-field center, smoking status, body mass index, low density lipoprotein cholesterol, high density lipoprotein
cholesterol, fibrinogen, von Willebrand factor, educational level, and total energy intake.
b Further adjusted for systolic blood pressure, use of antihypertensive medication, and diabetes mellitus.
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dietary and serum magnesium levels. Compared with the
group with less than median values of both dietary and serum
magnesium, the group with both dietary and serum magne-
sium greater than the median had a significant lower risk of
ischemic stroke (RR ¼ 0.64, 95%CI: 0.48, 0.85), but not the
groups with either dietary or serum magnesium below the
median.
DISCUSSION
The main findings of this prospective study were that
increased levels of serum magnesium were inversely asso-
ciated with the incidence of ischemic stroke in a population-
based sample of middle-aged men and women, although
there was a weak association between dietary magnesium
and the incidence of ischemic stroke. A previous study re-
ported that low levels of serum magnesium predicted neu-
rologic events, mainly ischemic stroke, in patients with
advanced atherosclerosis (20), although that study was per-
formed in a clinical setting and the sample size was rela-
tively small (n ¼ 323). Our results provide further evidence
that serum magnesium levels could be inversely associated
with the incidence of ischemic stroke in a large, biracial,
population-based cohort and that the associations may be
stronger among whites than blacks.
The mechanisms by which high serum magnesium levels
decrease the risk of ischemic stroke have not been fully
elucidated. Hypertension and diabetes mellitus could be
mediators between serum magnesium and the incidence of
ischemic stroke. In the present study, the inverse association
of serum magnesium with the incidence of ischemic stroke
was attenuated to a nonsignificant level after adjustment for
hypertension and diabetes status, and the contribution of
hypertension and diabetes status to the association between
serum magnesium and ischemic stroke was more than 95%.
Baseline serum magnesium was inversely associated with
blood pressure and the prevalence of hypertension and di-
abetes mellitus (1). Further, these associations were also
observed in prospective analyses (3, 7). On the other hand,
previous experimental studies have shown that low plasma
levels of magnesium accelerate atherogenesis by promoting
inflammation and oxidative modification. Magnesium defi-
ciency could be associated with the onset of an inflamma-
tory response leading to increased circulating levels of
cytokines, which trigger an oxidative response in endothe-
lial cells (21, 22). Moreover, magnesium deficiency could be
associated with the risk of thrombus formation. Platelet-
dependent thrombosis was significantly increased in patients
with stable coronary artery disease with low intracellular lev-
els of magnesium (23). In the present study, serummagnesium
levels were inversely associated with von Willebrand factor
levels, and previous studies indicated that von Willebrand
factor levels were positively associated with the incidence of
ischemic stroke (16).
Dietary magnesium was marginally inversely associated
with the incidence of ischemic stroke, and the association
was weaker than that with serum magnesium. A prospective
study of 43,738 US men reported that dietary magnesium
was inversely associated with the risk of total stroke, al-
though the association was stronger in hypertensive than
normotensive men, and the association was attenuated to
nonsignificant levels after adjustment for potassium and fi-
ber intake (5). In the Nurses’ Health Study, dietary magne-
sium was marginally inversely associated with increased
risk of ischemic stroke (6), consistent with our findings. In
the ARIC Study, the correlation coefficient between dietary
and serum magnesium was weak, and there was no associ-
ation of dietary magnesium with the incidence of
Table 5. Rate Ratios and 95% Confidence Intervals of Ischemic Stroke According to Combinations of Dietary and
Serum Magnesium Levels, Atherosclerosis Risk in Communities Study, 1987–2004
Combinations of Serum and Dietary Magnesiuma
1 2 3 4
No. at risk 3,618 3,378 2,999 3,275
Ischemic stroke
Person-years of follow-up 53,681 49,971 45,645 50,472
No. of cases 168 162 126 102
Incidence rate/1,000
person-years
3.1 3.2 2.8 2.0
Rate ratios (95%
confidence interval)
Age, sex, race, and
energy intake adjusted
Referent 0.97 (0.75, 1.25) 0.98 (0.78, 1.24) 0.64 (0.48, 0.85)
Multivariate adjustedb 1.05 (0.81, 1.35) 1.05 (0.83, 1.32) 0.74 (0.56, 0.98)
Multivariate adjustedc 0.99 (0.76, 1.47) 1.16 (0.92, 1.47) 0.81 (0.61, 1.09)
a Median values of combinations: 1 (serummagnesium,1.6 mEq/L; dietary magnesium,241mg/day); 2 (serum
magnesium, 1.6 mEq/L; dietary magnesium, >241 mg/day); 3 (serum magnesium, >1.6 mEq/L; dietary magne-
sium, 241 mg/day); 4 (serum magnesium, >1.6 mEq/L; dietary magnesium, >241 mg/day).
b Adjusted for age, sex, race-field center, smoking status, body mass index, low density lipoprotein cholesterol,
high density lipoprotein cholesterol, fibrinogen, von Willebrand factor, educational level, and total energy intake.
c Further adjusted for systolic blood pressure, use of antihypertensive medication, and diabetes mellitus.
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hypertension (7) or type 2 diabetes (3). In the present study,
dietarymagnesium intakewas inversely associatedwithLDL
cholesterol and positively associated with HDL cholesterol,
but serum magnesium levels were positively associated with
both LDL cholesterol and HDL cholesterol levels. Further,
other dietary factors could reduce the risk of ischemic stroke,
such as potassium and calcium intake (5, 6, 24, 25). These
were positively associated with dietary magnesium intake
but not with serum magnesium levels. Therefore, these dis-
crepancies in the relations of dietary and serum magnesium
with cardiovascular risk factors may explain, in part, the
different associations of dietary and serum magnesium with
incident ischemic stroke. On the other hand, compared with
serummagnesium levels, the relatively less precise measure-
ment of dietary magnesium intake could have resulted in
a type 2 error. Unfortunately, the ARIC Study did not have
information on supplemental magnesium intake, which
could lead to underestimation of dietary magnesium intake.
In addition, we did not examine the effect of magnesium
supplementation on the associations of dietary and serum
magnesiumwith incidence of ischemic stroke. Although val-
idity and reliability studies of our food frequency question-
naire have been conducted previously (13), the validity and
reliability of the assessment of dietary intake of magnesium
are unknown. Measurement error typically would lead to an
underestimation of the association of dietary magnesium
with the incidence of ischemic stroke.
In the present study, compared with the group with less
thanmedianvalues of both dietary and serummagnesium, the
group with both dietary and serum magnesium greater than
themedian had a 36% lower risk of ischemic stroke. This was
not true for the groups with either dietary or serum magne-
sium below the median. To our knowledge, this is the first
prospective study to report this joint association. Although
many intervention trials using magnesium supplementation
have been conducted to prevent hypertension, evidence of the
effect of magnesium on blood pressure is inconsistent (26). It
may be useful to monitor serummagnesium levels in a future
intervention study by using magnesium supplementation.
Potential limitations of this study warrant consideration.
First, we analyzed the associations between serum or dietary
magnesium and ischemic stroke incidence using a single
assessment of measurements at baseline, which may lead
to misclassification of the habitual magnesium levels of
some individuals. However, when we used the means of 2
visits to reanalyze the associations of serum and dietary
magnesium with ischemic stroke incidence, the results were
essentially unchanged. Second, serum magnesium accounts
for less than 1% of the whole-body magnesium level (27).
The serum magnesium level may not reflect magnesium
levels accurately in other tissues, but the serum magnesium
level has been shown to be correlated with the intracellular
free magnesium level (r ¼ 0.54) (28). Third, because treat-
ment of hypertension with diuretics could lower the serum
magnesium concentration (29), hypertension may be not
only a mediator but also a confounder between serum mag-
nesium and the incidence of ischemic stroke. In the present
study, however, the inverse association of serum magnesium
with the incidence of ischemic stroke was unchanged when
we excluded participants using diuretics. Finally, although
a large proportion of the inverse association of serum mag-
nesium with ischemic stroke incidence was explained by
hypertension and diabetes, other unmeasured factors related
to hypertension and diabetes, such as inflammation, endo-
thelial function, and insulin, may modify this conclusion.
In conclusion, low serum magnesium levels could be asso-
ciatedwith the risk of ischemic stroke, in part, via the effects of
hypertension and diabetes mellitus. Further study is needed to
confirm the association of dietary or serum magnesium with
hemorrhagic stroke in additional large prospective studies.
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